Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells
- 1 January 2021
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 182-184.e1
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 19 references indexed in Scilit:
- JAK inhibitors in dermatology: The promise of a new drug classJournal of the American Academy of Dermatology, 2017
- CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in MiceJournal of Investigative Dermatology, 2017
- Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of DiseaseJournal of Investigative Dermatology, 2017
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)Journal of the American Academy of Dermatology, 2016
- Tofacitinib Citrate for the Treatment of VitiligoJAMA Dermatology, 2015
- Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of VitiligoJournal of Investigative Dermatology, 2015
- Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo–Controlled StudyJournal of Investigative Dermatology, 2015
- CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of VitiligoScience Translational Medicine, 2014
- A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the SkinJournal of Investigative Dermatology, 2012
- VitiligoNew England Journal of Medicine, 2009